FDA rules on adaptive trials would help sector, says PI

By Gareth Macdonald

- Last updated on GMT

Related tags Adaptive trials Clinical trial Pharmacology

Definitive FDA guidance on adaptive trials cannot come soon enough for the pharmaceutical and biotech sectors, according to Perceptive Informatics (PI).

As the name suggests adaptive trials can be adjusted while they are in progress to improve the efficiency of the development process, target responsive subjects and reduce the number of patients exposed to candidates that prove to be ineffective.

A PI survey of 500 biopharma developers and contract research professionals ranked concerns about regulatory acceptance of data as the major stumbling block preventing greater use of adaptive trials.

Second and third on the list of worries about adaptive studies were: a lack of understanding of the techniques needed to carry out such trials, cited by 33 per cent of respondents; and confusion over access to clinical endpoint data, which was mentioned by 28 per cent of those who took part.

Other barriers to implementing adaptive trial designs included understanding and implementing complex statistical methodologies as well as difficulties in medication supplies estimation and supply chain management.

PI’s senior director Bill Byrom said that: "Formal FDA guidance on adaptive trials implementation is expected later this year and should help to alleviate regulatory acceptance concerns.

As biopharmaceutical companies focus on making reliable decisions as early as possible in drug development, a growing area for adaptive trials is the ability to include more dose levels in Phase II dose-finding studies without significantly increasing the number of study participants or timeline required​.”

The US Food and Drug Administration (FDA) has been developing its rules on adaptive trials since 2004 but is yet to issue any formal guidance.

PI, which is the eClinical arm of US contract research organisation (CRO) Parexel, provides a range of adaptive trial design services to the pharmaceutical industry with a particular focus on electronic data capture (EDC).

Related news

Show more

Related products

show more

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

4 Warning Signs Your Research Site Is in Trouble

4 Warning Signs Your Research Site Is in Trouble

Elligo Health Research® | 10-Mar-2023 | Insight Guide

You want your clinical research practice to be a success for your business and your patients, but how can you tell if it’s in trouble? Read this article...

How Sponsors Reduce Chaos in Decentralized Trials

How Sponsors Reduce Chaos in Decentralized Trials

Florence Healthcare | 08-Mar-2023 | Insight Guide

89% of research sponsors currently use and expect to continue the use of decentralized technologies and methods, according to our state of the industry...

2023 State of Clinical Trial Technology Report

2023 State of Clinical Trial Technology Report

Florence Healthcare | 01-Mar-2023 | Insight Guide

Discover the trends shaping clinical trial technology in 2023, from Site Enablement to eISFs, integrations, and site-sponsor collaboration. This report...

Related suppliers

Follow us


View more